Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CHEK2
REST API REST API
Homo sapiens
CHEK2 is differentially expressed in 233 experiments: 99 organism parts: bone marrow, prostate, ... (97 more);, 165 disease states: normal, glioblastoma, ... (163 more);, 66 cell types 295 cell lines 27 compound treatments and 62 other conditions.
Synonyms PP1425, bA444G7, CDS1, CHK2, RAD53, HuCds1
Orthologs Chek2 (Mus musculus)   ENSCING00000004987 (Ciona intestinalis)   chek2 (Danio rerio)   Chek2 (Rattus norvegicus)   Q58DJ9_BOVIN (Bos taurus)   A1EAT1_CHICK (Gallus gallus)   DUN1 (Saccharomyces cerevisiae)   lok (Drosophila melanogaster)   chek2 (Xenopus laevis)   CHEK2 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term chromosome, telomeric region, DNA damage checkpoint, protein binding, apoptosis, DNA damage response, signal transduction resulting in induction of apoptosis, metal ion binding, protein tyrosine kinase activity, ATP binding, cell cycle, transferase activity, transferring phosphorus-containing groups, nucleus, nucleotide binding, kinase activity, protein serine/threonine kinase activity, nucleoplasm, cell cycle checkpoint, response to DNA damage stimulus, response to gamma radiation, protein kinase activity, PML body, protein phosphorylation, replicative senescence, signal transduction in response to DNA damage
InterPro Term Prot_kinase_cat_dom, FHA_dom, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom
UniProt Accession B7ZBH9, B7ZBI0, B7ZBF2, B7ZBF6, B7ZBF7, B7ZBF8, O96017, Q9HBS5, C9JFD8, C9JFD7, E7EPP1, F8WCV2
Gene-Disease Assocation OSTEOGENIC SARCOMA, PROSTATE CANCER, BREAST CANCER, CHECKPOINT KINASE 2, S. POMBE, HOMOLOG OF; CHEK2, LI-FRAUMENI SYNDROME 2; LFS2
Search EB-eye ENSG00000183765
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-GEOD-1577, ... (24 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (33 experiments)

Factor Value U/D Experiments
DU145
2
E-GEOD-20089, E-GEOD-17482
HL-60
2
E-MTAB-37, E-GEOD-24147
MCF-7
2
E-GEOD-20081, E-GEOD-19639
MDA-MB-231
2
E-TABM-420, E-MTAB-62
SW480
1
2
E-GEOD-18005, E-MEXP-1014, E-MTAB-37
snb-19
1
E-MTAB-62
289 more value(s).


Cell type

studied in E-GEOD-20193, E-MEXP-66, E-GEOD-20677, E-GEOD-4219, E-GEOD-13987, ... (37 experiments)

Factor Value U/D Experiments
partially reprogrammed human induced pluripotent stem cell
2
E-GEOD-18265, E-GEOD-18147
human embryonic stem cell
1
2
E-GEOD-20033, E-GEOD-18265, E-GEOD-18147
CD8+ T cell
1
2
E-GEOD-19069, E-AFMX-5, E-TABM-145
primary fibroblast
1
E-MEXP-66
mature monocyte derived dendritic cell
1
E-GEOD-4984
secretory cell
1
E-GEOD-3998
60 more value(s).


Disease state

studied in E-MEXP-1922, E-GEOD-15960, E-GEOD-1869, E-GEOD-1577, E-TABM-15, ... (41 experiments)

Factor Value U/D Experiments
glioblastoma
3
E-MTAB-37, E-GEOD-4290, E-MTAB-62
prostate carcinoma
2
E-GEOD-96, E-MTAB-37
acute lymphoblastic leukemia
2
E-MTAB-37, E-GEOD-96
acute promyelocytic leukemia
2
E-GEOD-995, E-GEOD-96
colon carcinoma
2
E-MTAB-62, E-GEOD-3726
lymphoma
1
E-MTAB-62
159 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-5741, E-TABM-782, E-GEOD-5824, E-GEOD-3720, ... (18 experiments)

Factor Value U/D Experiments
none
3
4
E-GEOD-5824, E-TABM-782, E-MEXP-1958, E-GEOD-412, E-GEOD-995, ... (7 experiments)
NaOH
1
E-MEXP-2590
phorbol 12-myristate 13-acetate
1
E-GEOD-995
bacterial endotoxin
1
E-GEOD-3284
actinomycin D
1
E-GEOD-6400
Cxcl12
1
E-GEOD-7307
21 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
28
1
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (11 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-5999, E-GEOD-1614, E-GEOD-20033, E-MEXP-2359, E-MTAB-62 ... (5 experiments)

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-GEOD-21887

Environmental stress
studied in E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MTAB-73, E-GEOD-17385, E-MEXP-2340, E-MEXP-563

Genotype
studied in E-GEOD-1923, E-GEOD-3494, E-GEOD-21750, E-TABM-321, E-TABM-868, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-GEOD-20504, E-GEOD-9764, ... (7 experiments)

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-GEOD-19330, E-GEOD-19519, ... (21 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-MEXP-561

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-17636

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-11886, E-GEOD-11428

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-33562, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-19815, ... (6 experiments)

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-3494, E-GEOD-4922, E-TABM-147

Vehicle
studied in E-GEOD-5258

Processing time: 0.47 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM